A recent interview with Elaine Haynes, President & CEO of KaloCyte, maker of ErythroMer, an essential ingredient for a new human blood substitute.

This video segment features a recent Military exercise, where researchers unveiled a mockup of the product they hope will advance battlefield medicine – a shelf-stable human blood substitute.

This article highlights a recent report and lab visit by Military Times, spotlighting a breakthrough effort funded by Defense Advanced Research Projects Agency (DARPA) and developed by biotech firm KaloCyte in collaboration with researchers at the University of Maryland, Baltimore.

Military Times recently interviewed KaloCyte co-founder Allan Doctor as featured in this video on DARPA’s development of synthetic blood.

DARPA, the Pentagon’s research agency, is making strides in battlefield medicine with the development of a powdered blood substitute, seeking partnerships to advance testing. The program director expressed optimism about the potential of this innovative product, particularly in the context of modern military operations where traditional blood supply may face challenges.

KaloCyte’s work on ErythroMer is featured in this French article on artificial blood substitutes currently in development.

KaloCyte Co-Founders Dr. Allan Doctor and Dr. Dipanjan Pan are among several experts featured in this article on blood substitute research, showcasing KaloCyte’s development of ErythroMer.

Chrysea and KaloCyte have entered into an exclusive license agreement, forging a global partnership that combines Chrysea’s synthetic biology expertise in production of biosynthetic hemoglobin with KaloCyte’s innovative artificial red blood cell technology.

KaloCyte’s Chief Scientific Officer, Dr. Allan Doctor, was interviewed on German television for this feature showcasing development of ErythroMer. (in German, subtitles unavailable).

Dr. Allan Doctor, co-founder and chief scientific officer at KaloCyte, speaks with host Jacob Goldstein explaining the complex science behind artificial blood, and how this innovation could help save millions of lives.